|Awarded On||May 20, 2015|
|Title||Turning on a Novel Tumor-Inhibiting Switch for Colorectal Cancer|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas Health Science Center at San Antonio|
|Principal Investigator/Program Director||Rong Li|
It is known that estrogen is associated with reduced incidence of colorectal cancer (CRC). Estrogen effects in general are mediated by two estrogen receptors called ER-alpha and ER-beta, which play different and even opposite roles in cancer. The CRC-reducing effect of estrogen has been largely attributed to the action of ER-beta. Because estrogen itself is unlikely to be clinically useful due to its known ER-alpha-mediated side effects, rallying the antitumor activity of ER-beta through ER-beta-specific pathways represents a promising approach for CRC treatment and prevention. In the current proposal, researchers with highly complementary expertise will determine whether a clinically safe E...